351 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 11 of 11
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
You are being invited to take part in a research study that includes studying JNJ-78278343 in subjects with prostate cancer. This is an investigational drug which means that this is a new approach for the treatment of people who have prostate cancer. The main purpose of this study is to find a…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main goal of a research study is to learn things to help patients in the future. The decision to join or not join the research study will not cause you to lose any medical benefits. If you decide not to take part in this study, your doctor will continue to treat you. The purpose of this study is to learn more about prostate…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO alone. ONC-392 has…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to assess the efficacy of a home-delivered whole-food plant-based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA-approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 68Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to find out if ASP3082 is effective and safe as a treatment in advanced cancers with KRAS G12D mutation. ASP3082 may work by directing proteins found in your body to block the growth of cancer cells. This is the first study where ASP3082 is being tested in humans. Cancers include bladder cancer, breast cancer, colon and rectal…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-…
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Currently Recruiting
IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not "on the market" (available for you to receive a prescription for and/or to buy) in any country. The main goals of the study are to determine the safety, tolerability, and effects of IDE397 used as…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE